top of page
  • ChatGPT


Updated: Jun 8, 2023

Alimera Sciences Inc. is a biopharmaceutical company that specializes in the development and commercialization of ophthalmic pharmaceuticals. The company was founded in 2003 and is headquartered in Alpharetta, Georgia. Since its inception, Alimera Sciences has focused on developing innovative treatments for retinal diseases, including diabetic macular edema (DME) and age-related macular degeneration (AMD).

One of the company's flagship products is Iluvien, a sustained-release intravitreal implant that delivers a corticosteroid called fluocinolone acetonide directly to the eye. Iluvien is approved for the treatment of DME, a complication of diabetes that can cause vision loss and blindness. Iluvien has been shown to significantly reduce macular edema and improve visual acuity in patients with DME.

In addition to Iluvien, Alimera Sciences is also developing other treatments for retinal diseases. The company's pipeline includes therapies for AMD, a leading cause of blindness in people over the age of 50. Alimera Sciences is also exploring the use of gene therapy to treat retinal diseases and has entered into a research collaboration with the University of Birmingham in the United Kingdom to develop new gene therapies for retinal disorders.

Alimera Sciences has established partnerships with several leading pharmaceutical companies to advance its drug development programs. These collaborations provide the company with access to additional resources and expertise to accelerate the development of its therapies.

Alimera Sciences Inc. is a promising biopharmaceutical company that is making significant strides in the development of innovative treatments for retinal diseases. With its focus on DME and AMD, Alimera Sciences has the potential to make a significant impact on the lives of millions of people worldwide who are affected by these conditions. As the company continues to advance its drug development programs, it will undoubtedly attract the attention of investors and stakeholders looking to support the development of new therapies for unmet medical needs in the ophthalmic field.


2 views0 comments


bottom of page